Pathophysiological theories of schizophrenia and its prevalence

Cover Page

Cite item

Abstract

in the modern world, schizophrenia is one of the most common and severe mental disorders that are known today. This disease affects both the social and professional spheres of life of the patient and his relatives. Modern research shows that men are more likely to suffer from schizophrenia, unlike women. In them, this disease usually begins earlier and is more severe. The manifestation of schizophrenia in women occurs later in life. Schizophrenia is considered one of the most complex and disabling diseases that have a significant impact not only on an individual's life, but also on society. There is little information about its nature and origin. Modern pharmacotherapy of schizophrenia is based mainly on dopaminergic and serotonergic antagonists/partial agonists, however, new discoveries in the pathophysiology of schizophrenia will significantly expand the range of new approaches in pharmacotherapy and identify more reliable biomarkers of the disease. The purpose of this review is to provide the latest pathophysiological theories of the occurrence of schizophrenia and to examine the prevalence of this disease in the city of Penza in 2024.

About the authors

O. O Solomanina

Penza State University

Email: solomanina2010@yandex.ru

N. S Kondratyeva

Penza State University

Email: kondratiewa.nina2016@yandex.ru

S. M Bodrova

Penza State University

Email: sofya.bodrova.2004@mail.ru

References

  1. Колгашкин А.Ю., Надеждин А.В. Связь между потреблением каннабиса и психозами – современный взгляд на проблему. Повествовательный обзор литературы // Медицина. 2021. №4. С. 76 – 100.
  2. Behnam V. Stress and the Role of the Gut – Brain Axis in the Pathogenesis of Schizophrenia: A Literature Review // International Journal of Molecular Sciences. 2020. Vol. 22, No. 18. P. 1 – 13.
  3. Blokhin I. O., Khorkova O. Molecular mechanisms of psychiatric diseases // Neurobiology of Disease. 2020. Vol. 146, No. 105136. P. 1 – 15.
  4. Grayson D.R., Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders // Neuropsychopharmacology. 2013. Vol. 38. No. 1. P. 138 – 166.
  5. Hindley G. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis // The Lancet Psychiatry. 2020. Vol. 7. No. 4. P. 344 – 353.
  6. Howes O.D., McCutcheon R., Owen M.J., Murray R.M. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia // Biological Psychiatry. 2017. Vol. 21. No. 1. P. 9 – 20.
  7. Howes O.D., McCutcheon R.A., Stone J. Glutamate and dopamine in schizophrenia: an update for the 21 century // Journal of Psychopharmacology. 2015. Vol. 29. No. 2. P. 97 – 115.
  8. Michael J. Owen, Sophie E. Legge, Elliott Rees Genomic findings in schizophrenia and their implications // Molecular Psychiatry. 2023. Vol. 28. No. 9. P. 1 – 10.
  9. Nordstr?m A.L., Farde L., Wiesel F.A. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients // Biological Psychiatry. 1993. Vol. 33. No. 4. P. 227 – 235.
  10. Carnac T. chizophrenia Hypothesis: Autonomic Nervous System Dysregulation of Fetal and Adult Immune Tolerance // Hypothesis and theory. 2022. Vol. 16. No. 844383. P. 15 – 25.
  11. Szeligowski T., Lim A. The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications // Frontiers in Psychiatry. 2020. Vol. 11. No. 156. P. 1 – 10.
  12. Tsegay E.W., Demise D.G., Hailu N.A., Gufue Z.H. Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia // Neuropsychiatric Disease and Treatment. 2020. Vol. 16. No. 20. P. 2499 – 2509.
  13. Uno Y., Coyle J.T. Glutamate hypothesis in schizophrenia // Psychiatry and Clinical Neurosciences. 2019. Vol. 73. No. 5. P. 204 – 215.

Supplementary files

Supplementary Files
Action
1. JATS XML

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).